Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Eligible age
18+ yrs
Accepts
All genders
Locations
40 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. It is not yet known if giving rituximab or mosunetuzumab works better in treating patients with follicular lymphoma with a low tumor burden.
Sponsor: National Cancer Institute (NCI)
You may qualify if…
- ✓ Participants must have a histologically confirmed diagnosis of classic follicular lymphoma (cFL). cFL was previously categorized as grade 1-3A per World Health Organization (WHO)-HAEM4R, but grading of classic follicular lymphoma (FL) is no longer mandatory.
- ✓ NOTE: Participants with follicular lymphoma with uncommon features (uFL) are eligible, including FL with diffuse growth pattern (dFL). Diagnosis is as per local pathology. Lymphoma fluorescence in situ hybridization (FISH) is not required. Molecular testing is not required.
- ✓ Participants must not have follicular lymphoma with "blastoid" or "large centrocyte" cytological features, or follicular large B-cell lymphoma (FLBL) (previously categorized as follicular lymphoma grade 3B)
- ✓ Participants must have low-tumor burden follicular lymphoma defined as:
- ✓ Nodal or extra-nodal tumor mass with diameter less than 7 cm in its greater diameter
- ✓ Involvement of no more than 3 nodal or extra nodal sites with diameter greater than 3 cm.
- ✓ Absence of B symptoms which may include unexplained fever, drenching sweats, unintentional weight loss (more than 10% of body weight)
- ✓ No symptomatic splenomegaly
Where it's recruiting
Birmingham
Phoenix · Tucson
Fayetteville · Little Rock · Rogers · Springdale
Beverly Hills · Duarte · Irvine · Lancaster …
Aurora · Fort Collins · Greeley · Loveland
Newark
Washington D.C.
Aventura · Coral Gables · Coral Springs · Deerfield Beach …
Atlanta · Augusta
Boise · Caldwell · Coeur d'Alene · Nampa …
Bloomington · Canton · Carthage · Chicago …
Crown Point · Dyer · Hobart · Indianapolis …
Source: ClinicalTrials.gov · NCT06337318 · last updated 2026-11-18